MX2016000121A - Tratamiento de lesiones inflamatorias de rosacea con invermectina. - Google Patents
Tratamiento de lesiones inflamatorias de rosacea con invermectina.Info
- Publication number
- MX2016000121A MX2016000121A MX2016000121A MX2016000121A MX2016000121A MX 2016000121 A MX2016000121 A MX 2016000121A MX 2016000121 A MX2016000121 A MX 2016000121A MX 2016000121 A MX2016000121 A MX 2016000121A MX 2016000121 A MX2016000121 A MX 2016000121A
- Authority
- MX
- Mexico
- Prior art keywords
- ivermectin
- treatment
- rosacea
- inflammatory lesions
- once daily
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J9/00—Feeding-bottles in general
- A61J9/06—Holders for bottles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen métodos para el tratamiento seguro y eficaz de lesiones inflamatorias de rosácea en un sujeto; los métodos implican aplicar tópicamente una vez al día a un área afectada de la piel una composición tópica que contiene ivermectina y un portador farmacéuticamente aceptable; ha sido demostrado que el tratamiento tópico de una vez al día con ivermectina es apreciablemente superior que el tratamiento tópico de dos veces al día con metronidazol para reducir los conteos de lesiones inflamatorias.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361843540P | 2013-07-08 | 2013-07-08 | |
US201361919208P | 2013-12-20 | 2013-12-20 | |
US201461927717P | 2014-01-15 | 2014-01-15 | |
US14/209,927 US9233117B2 (en) | 2013-07-08 | 2014-03-13 | Treatment of inflammatory lesions of rosacea with ivermectin |
PCT/US2014/045717 WO2015006305A1 (en) | 2013-07-08 | 2014-07-08 | Treatment of inflammatory lesions of rosacea with ivermectin |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016000121A true MX2016000121A (es) | 2016-07-14 |
Family
ID=52133217
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016000122A MX2016000122A (es) | 2013-07-08 | 2014-07-08 | Tratamiento de rosacea papulopustular con invermectina. |
MX2016000121A MX2016000121A (es) | 2013-07-08 | 2014-07-08 | Tratamiento de lesiones inflamatorias de rosacea con invermectina. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016000122A MX2016000122A (es) | 2013-07-08 | 2014-07-08 | Tratamiento de rosacea papulopustular con invermectina. |
Country Status (17)
Country | Link |
---|---|
US (12) | US9233117B2 (es) |
EP (2) | EP3019173A1 (es) |
JP (7) | JP6438466B2 (es) |
KR (2) | KR101864799B1 (es) |
CN (4) | CN111467301A (es) |
AU (2) | AU2014287422B2 (es) |
BR (2) | BR112016000350A8 (es) |
CA (2) | CA2916668A1 (es) |
CL (2) | CL2016000009A1 (es) |
HK (2) | HK1223841A1 (es) |
IL (3) | IL243315B (es) |
MX (2) | MX2016000122A (es) |
NZ (2) | NZ716034A (es) |
RU (2) | RU2633481C2 (es) |
SG (2) | SG11201510420UA (es) |
WO (2) | WO2015006305A1 (es) |
ZA (1) | ZA201600358B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6448641B2 (ja) | 2013-11-29 | 2019-01-09 | ガルデルマ・ソシエテ・アノニム | アトピー性皮膚炎の治療及び/又は予防のためのアベルメクチンファミリー又はミルベマイシンファミリーの化合物 |
FR3032616B1 (fr) * | 2015-02-12 | 2017-02-24 | Galderma Sa | Compose de la famille des avermectines pour le traitement et/ou la prevention des folliculites |
EP3377063B1 (en) | 2015-11-17 | 2023-08-09 | Galderma S.A. | Use of ivermectin and brimonidine in the treatment and/or prevention of moderate to severe rosacea |
US10874682B2 (en) * | 2016-08-04 | 2020-12-29 | Nestlé Skin Health Sa | Compositions and the use thereof for treating or preventing rosacea |
CN106397233A (zh) * | 2016-08-26 | 2017-02-15 | 南通奥凯生物技术开发有限公司 | 一种医药级乙二胺四乙酸二钠的制备方法 |
US11160780B2 (en) * | 2016-09-30 | 2021-11-02 | Aurobindo Pharma Ltd. | Pharmaceutical composition of ivermectin and process for preparation thereof |
BR112020012018A2 (pt) | 2017-12-15 | 2020-11-24 | Tarsus Pharmaceuticals, Inc. | formulações de parasiticida de isoxazolina e métodos para tratar blefarite |
JP7129005B2 (ja) * | 2018-09-28 | 2022-09-01 | Toto株式会社 | 水洗大便器 |
WO2020172101A1 (en) | 2019-02-18 | 2020-08-27 | Mary Kay Inc. | Topical skin compositions for treating rosacea and skin redness |
CN111728959B (zh) * | 2020-08-11 | 2023-02-03 | 黑龙江天龙药业有限公司 | 一种抑制油脂分泌且清螨虫的鼻膜贴及其制备方法 |
EP4062907A1 (fr) | 2021-03-23 | 2022-09-28 | Substipharm | Formulation par voie orale d'ivermectine et utilisations |
JPWO2022269665A1 (es) * | 2021-06-21 | 2022-12-29 | ||
KR102346125B1 (ko) | 2021-10-15 | 2022-01-03 | (주)나비바이오텍 | 이버멕틴 정성 검사용 래피드 키트 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ197796A (en) | 1980-08-04 | 1984-11-09 | Merck & Co Inc | Stabilised aqueous formulations containing ivermectin |
US5332577A (en) | 1988-12-27 | 1994-07-26 | Dermamed | Transdermal administration to humans and animals |
US5656280A (en) | 1994-12-06 | 1997-08-12 | Helene Curtis, Inc. | Water-in-oil-in-water compositions |
FR2754452B1 (fr) | 1996-10-11 | 2003-02-14 | Oreal | Emulsion h/e a forte teneur en electrolytes et leur utilisation en dermo-cosmetique, notamment pour traiter les phenomenes d'irritation et/ou de peaux sensibles |
US5952372A (en) | 1998-09-17 | 1999-09-14 | Mcdaniel; William Robert | Method for treating rosacea using oral or topical ivermectin |
FR2787322B1 (fr) | 1998-12-18 | 2002-10-18 | Galderma Res & Dev | Emulsion huile-dans-eau comprenant un agent actif micronise et un systeme emulsionnant approprie |
US6133310A (en) | 1999-08-26 | 2000-10-17 | Parks; L. Dean | Method of treatment of rosacea |
US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
US6399651B1 (en) | 2000-06-29 | 2002-06-04 | L. Dean Parks | Method of treating dermatoses using avermectin compound |
US6399652B1 (en) | 2000-06-29 | 2002-06-04 | L. Dean Parks | Method of treating acne vulgaris using avermectin compound |
US6319945B1 (en) | 2000-06-29 | 2001-11-20 | L. Dean Parks | Method of treatment of seborrheic dermatitis |
DE10063946A1 (de) | 2000-12-20 | 2002-07-04 | Basf Ag | Verwendung von Lichtschutzmittelkombinationen, die als wesentlichen Bestandteil 2,2'-p-Phenylen-bis(3,1-benzoxazin-4-on) enthalten als photostabile UV-Filter in kosmetischen und pharmazeutischen Zubereitungen |
AU2003215011A1 (en) | 2002-02-08 | 2003-09-02 | Mcneil-Ppc, Inc. | Topical ivermectin composition |
AU2003225651A1 (en) | 2002-03-04 | 2003-09-22 | Divergence, Inc. | Nematicidal fatty acid and fatty acid ester related compounds |
MXPA05011208A (es) | 2003-04-24 | 2005-12-14 | Galderma Sa | Uso de ivermectina para el tratamiento de desordenes dermatologicos. |
FR2854074B1 (fr) * | 2003-04-24 | 2007-11-23 | Galderma Res & Dev | Utilisation de l'ivermectine pour le traitement de desordres dermatologiques |
EP1600158A1 (en) | 2004-05-26 | 2005-11-30 | Galderma Research & Development, S.N.C. | Use of ondansetron for the treatment of inflammation, and pharmaceutical compositions thereof |
DE602005020912D1 (de) | 2004-03-18 | 2010-06-10 | Galderma Sa | Ivermectin enthaltende creme |
FR2867684B1 (fr) * | 2004-03-18 | 2006-05-05 | Galderma Sa | Gel creme contenant de l'ivermectine |
FR2883181B1 (fr) | 2005-03-17 | 2007-05-18 | Galderma Sa | Composition a base d'une avermectine et d'acide azelaique notamment pour le traitement de la rosacee |
FR2886850B1 (fr) | 2005-06-10 | 2007-10-05 | Galderma Sa | Composition a base d'une avermectine et de peroxyde de benzoyle notamment pour le traitement de la rosacee |
FR2886852B1 (fr) | 2005-06-10 | 2007-11-23 | Galderma Sa | Composition a base d'une avermectine et d'hydrocortisone notamment pour le traitement de la rosacee |
FR2886851B1 (fr) | 2005-06-10 | 2007-10-05 | Galderma Sa | Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee |
FR2894823B1 (fr) | 2005-12-20 | 2008-02-29 | Galderma Sa | Composition de type emulsion inverse comprenant de l'ivermectine, et ses utilisations en cosmetique et en dermatologie |
FR2900052B1 (fr) | 2006-04-19 | 2011-02-18 | Galderma Sa | Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine |
FR2906468B1 (fr) | 2006-09-28 | 2012-09-21 | Galderma Sa | Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques |
FR2907012B1 (fr) | 2006-10-12 | 2012-09-21 | Galderma Sa | Composition dermatologique comprenant des nanocapsules d'avermectine, son procede de preparation et son utilisation |
FR2907013B1 (fr) | 2006-10-12 | 2012-09-21 | Galderma Sa | Produits de soin cutane a double compartiment comprenant de l'ivermectine, et leurs utilisations |
WO2010072958A2 (fr) | 2008-12-23 | 2010-07-01 | Galderma S.A. | Composition pharmaceutique topique comprenant un principe actif sensible a l'eau |
JP2012516320A (ja) | 2009-01-30 | 2012-07-19 | イッスム リサーチ デベロプメント カンパニー オブ ザ ヘブライ ユニバーシティ オブ エルサレム リミテッド | 爪および皮膚を処置するための組成物 |
FR2942138A1 (fr) * | 2009-02-16 | 2010-08-20 | Galderma Res & Dev | Association de composes pour le traitement ou la prevention des affections dermatologiques |
FR3000397A1 (fr) | 2012-12-31 | 2014-07-04 | Galderma Res & Dev | Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee |
-
2014
- 2014-03-13 US US14/209,927 patent/US9233117B2/en active Active
- 2014-03-13 US US14/209,958 patent/US9233118B2/en active Active
- 2014-04-21 US US14/257,567 patent/US9089587B2/en active Active
- 2014-07-08 CA CA2916668A patent/CA2916668A1/en not_active Abandoned
- 2014-07-08 JP JP2016525425A patent/JP6438466B2/ja active Active
- 2014-07-08 RU RU2016103753A patent/RU2633481C2/ru active
- 2014-07-08 CN CN202010479408.7A patent/CN111467301A/zh active Pending
- 2014-07-08 WO PCT/US2014/045717 patent/WO2015006305A1/en active Application Filing
- 2014-07-08 AU AU2014287422A patent/AU2014287422B2/en not_active Ceased
- 2014-07-08 EP EP14742711.6A patent/EP3019173A1/en not_active Ceased
- 2014-07-08 AU AU2014287408A patent/AU2014287408B2/en active Active
- 2014-07-08 CA CA2916704A patent/CA2916704C/en not_active Expired - Fee Related
- 2014-07-08 JP JP2016525418A patent/JP2016526572A/ja active Pending
- 2014-07-08 SG SG11201510420UA patent/SG11201510420UA/en unknown
- 2014-07-08 CN CN202010285877.5A patent/CN111494399A/zh active Pending
- 2014-07-08 WO PCT/US2014/045739 patent/WO2015006319A1/en active Application Filing
- 2014-07-08 SG SG11201510635PA patent/SG11201510635PA/en unknown
- 2014-07-08 MX MX2016000122A patent/MX2016000122A/es unknown
- 2014-07-08 RU RU2016103715A patent/RU2633076C2/ru active
- 2014-07-08 BR BR112016000350A patent/BR112016000350A8/pt not_active Application Discontinuation
- 2014-07-08 US US14/903,949 patent/US20160184342A1/en not_active Abandoned
- 2014-07-08 BR BR112016000335A patent/BR112016000335A8/pt not_active Application Discontinuation
- 2014-07-08 MX MX2016000121A patent/MX2016000121A/es unknown
- 2014-07-08 KR KR1020167003495A patent/KR101864799B1/ko active IP Right Grant
- 2014-07-08 KR KR1020167003494A patent/KR101863085B1/ko active IP Right Grant
- 2014-07-08 NZ NZ716034A patent/NZ716034A/en unknown
- 2014-07-08 EP EP14742712.4A patent/EP3019174A1/en not_active Withdrawn
- 2014-07-08 CN CN201480039404.XA patent/CN105828825A/zh active Pending
- 2014-07-08 NZ NZ716033A patent/NZ716033A/en unknown
- 2014-07-08 CN CN201480039403.5A patent/CN105792829A/zh active Pending
-
2015
- 2015-12-17 US US14/973,055 patent/US20160143935A1/en not_active Abandoned
- 2015-12-17 US US14/973,037 patent/US20160175337A1/en not_active Abandoned
- 2015-12-24 IL IL243315A patent/IL243315B/en unknown
- 2015-12-24 IL IL243314A patent/IL243314B/en unknown
-
2016
- 2016-01-05 CL CL2016000009A patent/CL2016000009A1/es unknown
- 2016-01-05 CL CL2016000008A patent/CL2016000008A1/es unknown
- 2016-01-15 ZA ZA201600358A patent/ZA201600358B/en unknown
- 2016-10-24 HK HK16112205.8A patent/HK1223841A1/zh unknown
- 2016-10-24 HK HK16112206.7A patent/HK1223842A1/zh unknown
-
2017
- 2017-06-15 JP JP2017117452A patent/JP2017197562A/ja active Pending
-
2018
- 2018-02-22 US US15/902,109 patent/US20180177813A1/en not_active Abandoned
- 2018-03-01 US US15/909,090 patent/US20180207188A1/en not_active Abandoned
- 2018-05-24 US US15/988,368 patent/US10206939B2/en active Active
- 2018-07-19 JP JP2018135780A patent/JP6653734B2/ja active Active
- 2018-12-27 JP JP2018244191A patent/JP2019073527A/ja active Pending
-
2019
- 2019-08-23 US US16/549,405 patent/US20200000835A1/en not_active Abandoned
-
2020
- 2020-04-20 IL IL274058A patent/IL274058B/en unknown
- 2020-12-28 JP JP2020218114A patent/JP2021059590A/ja active Pending
-
2021
- 2021-02-18 US US17/178,542 patent/US20210177882A1/en not_active Abandoned
-
2022
- 2022-07-07 US US17/811,226 patent/US20220347198A1/en active Pending
-
2023
- 2023-01-19 JP JP2023006245A patent/JP2023052490A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ716034A (en) | Treatment of inflammatory lesions of rosacea with ivermectin | |
PH12019501197A1 (en) | Therapeutically active compounds and their methods of use | |
WO2015003355A3 (en) | Therapeutically active compounds and their methods of use | |
EP3063163A4 (en) | Nicotinamide riboside compositions for topical use in treating skin conditions | |
HK1222509A1 (zh) | 身體的皮膚病區域中的局部銅離子治療物 | |
PH12014501561A1 (en) | Therapeutically active compounds and their methods of use | |
MX2015010190A (es) | Metodos de tratamiento topico para infecciones microbianas. | |
CO2018001375A2 (es) | Composiciones de retinoides tópicos | |
EP3003045A4 (en) | Topical copper ion treatments in the genital-rectal areas of the body | |
HK1222575A1 (zh) | 局部銅離子治療物以及製備用於身體不同解剖區域中的局部銅離子治療物的方法 | |
HRP20170198T1 (hr) | Pripravci koji sadrže kondroitin-sulfat, natokinazu i sulfhidrilne spojeve za upotrebu u liječenju upale | |
HK1225317A1 (zh) | 用於治療過度出汗的局部組合物及其使用方法 | |
EP3065725A4 (en) | Use of cysteamine and derivatives thereof to treat mitochondrial diseases | |
BR112015027436A2 (en) | Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients | |
PH12016500726B1 (en) | Topical anti-inflammatory pharmaceutical composition with zileuton cream formulation | |
EP3056206A4 (en) | Icotinib-containing topical skin pharmaceutical composition and use thereof | |
WO2015063613A3 (en) | Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents | |
PT3125865T (pt) | Associação de ingredientes ativos para utilização tópica na restruturação da barreira cutânea alterada depois de doenças cutâneas | |
EP2956216A4 (en) | TOPICAL COMPOSITION FOR STIMULATING LAYERS OF EPIDERM AND DERMAL SKIN | |
IL225613A0 (en) | Cosmetic formulation for local skin care | |
IN2013DE02943A (es) | ||
UA92452U (ru) | Способ заживления местных лучевых повреждений кожи | |
PL2706994T3 (pl) | Farmaceutyczna kompozycja miejscowa do stosowania w leczeniu i/lub profilaktyce zakażeń zmian skórnych |